Currently, there are 56.52M common shares owned by the public and among those 42.91M shares have been available to trade.
The company’s stock has a 5-day price change of 5.00% and -32.85% over the past three months. BDTX shares are trading 7.94% year to date (YTD), with the 12-month market performance down to -23.26% lower. It has a 12-month low price of $1.91 and touched a high of $7.66 over the same period. BDTX has an average intraday trading volume of 545.59K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.74%, -9.03%, and -48.36% respectively.
Institutional ownership of Black Diamond Therapeutics Inc (NASDAQ: BDTX) shares accounts for 75.33% of the company’s 56.52M shares outstanding.
It has a market capitalization of $130.71M and a beta (3y monthly) value of 2.50. The earnings-per-share (ttm) stands at -$1.36. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.87% over the week and 7.79% over the month.
Earnings per share for the fiscal year are expected to increase by 30.85%, and 5.93% over the next financial year.
Looking at the support for the BDTX, a number of firms have released research notes about the stock. Raymond James stated their Outperform rating for the stock in a research note on July 31, 2024, with the firm’s price target at $20. Stifel was of a view on June 30, 2023 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on June 28, 2023, issuing a price target of $11. Wedbush on their part issued Outperform rating on June 27, 2023.
